Periochip
NDC Package 64239-101-20

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Periochip is a . Marketed by Dexcel Pharma Technologies Ltd., this product is identified by NDC 64239-101 and is authorized under FDA application NDA020774.

Identification & Billing

NDC Package Code
64239-101-20
Package Description
2 BLISTER PACK in 1 CARTON / 10 INSERT, EXTENDED RELEASE in 1 BLISTER PACK
Product Code
64239-101
11-Digit Billing Format
64239010120

Clinical Specifications

Proprietary Name
Periochip
Dosage Form
-

Regulatory & Marketing

Labeler Name
Dexcel Pharma Technologies Ltd.
FDA Application #
NDA020774
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
05-01-1998
End Marketing Date
06-30-2023
Listing Expiration
06-30-2023
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 64239-101-20 identifies a specific commercial package of 2 blister pack in 1 carton / 10 insert, extended release in 1 blister pack of Periochip, labeled by Dexcel Pharma Technologies Ltd.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Dexcel Pharma Technologies Ltd. on May 01, 1998. The current certification is valid through June 30, 2023.

How is this Dexcel Pharma Technologies Ltd. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 64239010120. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
64239-101-20
11-Digit CMS (5-4-2)
64239-0101-20

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.